Literature DB >> 10553708

Quinolone activity against anaerobes.

P C Appelbaum1.   

Abstract

The first generation of fluoroquinolones such as ciprofloxacin and ofloxacin are inactive against most anaerobic bacteria. However, some broad-spectrum quinolones, which have recently become clinically available or are under active development, have significant antianaerobic activity. This review summarises the in vitro activity of currently available, as well as experimental, quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxacin, ofloxacin, levofloxacin, fleroxacin, pefloxacin, enoxacin and lomefloxacin. Compounds with intermediate antianaerobic activity include sparfloxacin and grepafloxacin. Trovafloxacin, gatifloxacin and moxifloxacin yield low MICs against most groups of anaerobes. Quinolones with the greatest in vitro activity against anaerobes include clinafloxacin and sitafloxacin (DU-6859a).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553708     DOI: 10.2165/00003495-199958002-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  31 in total

1.  Reduction of oral flora with ciprofloxacin in healthy volunteers.

Authors:  P C Appelbaum; S K Spangler; M Strauss
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

2.  Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.

Authors:  M A Cooper; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1991-09       Impact factor: 5.790

3.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.

Authors:  M R Jacobs; S K Spangler; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1990-09       Impact factor: 5.790

5.  Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.

Authors:  N Kato; H Kato; K Tanaka-Bandoh; K Watanabe; K Ueno
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

6.  In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

7.  Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

8.  In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.

Authors:  R Wise; J M Andrews; G Danks
Journal:  J Antimicrob Chemother       Date:  1984-03       Impact factor: 5.790

9.  Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

10.  In vitro activity of DU-6859a against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

View more
  13 in total

1.  Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Andrew E Simor; Alex Kopp; Paula A Rochon; David N Juurlink
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 3.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.

Authors:  Aditi Mulgaonkar; Jürgen Venitz; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

5.  A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron.

Authors:  S Miyamae; O Ueda; F Yoshimura; J Hwang; Y Tanaka; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

6.  Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.

Authors:  David W Hecht; J R Osmolski
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 7.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.

Authors:  D A Gajjar; A Bello; Z Ge; L Christopher; D M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Effect of parenteral fluoroquinolone administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract.

Authors:  Curtis J Donskey; Marion S Helfand; Nicole J Pultz; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Authors:  Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Lewis R Somberg; Atilla Nakeeb; Robert A Cambria; Jonathan B Towne
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.